Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2020 Jul 27;13(10):877–888. doi: 10.1158/1940-6207.CAPR-20-0216

Table 2.

Urinary PGE-M concentration according to randomized intervention arm.

Aspirin dose assignment
Variable Placebo (n=58) 81 mg/day (n=57) P81 v. placebo 325 mg/day (n=54) P325 v. placebo Paspirin (grouped) v. placebo
Baseline urinary PGE-M, ng/mg Cr 15.5 (12.6) 17.7 (17.1) 0.44 14.3 (13.7) 0.62 0.82
Post-Intervention urinary PGE-M, ng/mg Cr 16.4 (15.8) 13.1 (13.4) 0.24 9.4 (7.9) 0.005 0.018
Δ urinary PGE-M, ng/mg Cr 0.8 (11.8) −4.6 (17.7) 0.056 −4.9 (11.2) 0.010 0.015
% Change 8.5 (50.6) −15.4 (56.7) 0.018 −28.2 (40.3) <0.0001 0.0003

The p-value for the primary outcome comparison is in Bold. Values are mean (SD) unless otherwise noted. P-values are generated from unpaired t-tests between groups, as noted by the subscript text, for each measure. No significant differences were observed between aspirin treatment groups (81 mg/day v. 325 mg/day), all p>0.05.